Spots Global Cancer Trial Database for olaparib
Every month we try and update this database with for olaparib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | NCT03205176 | Malignant Solid... Lymphoma Ovarian Cancer Breast Cancer Pancreatic Canc... Prostate Cancer | AZD5153 Olaparib | 18 Years - 130 Years | AstraZeneca | |
| Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | NCT02485990 | Primary Periton... | Tremelimumab Olaparib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | NCT01116648 | Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Ovarian Serous ... Ovarian Serous ... Primary Periton... Triple-Negative... | Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients | NCT04152941 | Relapsed Ovaria... | Olaparib | 18 Years - | ARCAGY/ GINECO GROUP | |
| Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study | NCT04091204 | BRCA Wild Type ... | Olaparib tablet... | 18 Years - | National Cancer Institute, Naples | |
| Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | NCT02484404 | Colorectal Neop... Breast Neoplasm... | Olaparib Cediranib Durvalumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma | NCT01583543 | Ewing's Sarcoma | Olaparib | 18 Years - | Massachusetts General Hospital | |
| Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd | NCT06298084 | Breast Cancer M... HER2-positive M... HER2 Low Breast... Advanced Breast... | Patritumab deru... Olaparib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis | NCT03317392 | Castration-Resi... Metastatic Pros... Stage IVB Prost... | Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Magnetic Resona... Olaparib Quality-of-Life... Radium Ra 223 D... | 18 Years - | National Cancer Institute (NCI) | |
| HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer | NCT03685331 | Metastatic Brea... Locally Advance... Advanced Breast... BRCA2 Mutation BRCA1 Mutation | Palbociclib Olaparib Fulvestrant | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Study of Pembrolizumab and Olaparib in Bile Duct Cancer | NCT04306367 | Cholangiocarcin... | Pembrolizumab Olaparib | 18 Years - | Georgetown University | |
| Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer | NCT05501548 | Prostate Cancer Castration-resi... | Olaparib Vitamin C | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. | NCT01924533 | Gastric Cancer | Olaparib Paclitaxel Placebo | 18 Years - 99 Years | AstraZeneca | |
| Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | NCT06065059 | Breast Cancer Ovarian Cancer Pancreas Cancer Prostate Cancer BRCA1 Mutation BRCA-Mutated Ov... BRCA-Associated... HRD Positive Ad... | TNG348 Olaparib | 18 Years - | Tango Therapeutics, Inc. | |
| Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. | NCT05340413 | HER2-negative B... Metastatic Brea... Triple Negative... | Olaparib | 18 Years - | SOLTI Breast Cancer Research Group | |
| Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | NCT02898207 | Metastatic High... Metastatic Mali... Metastatic Prim... Metastatic Trip... Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Breas... Recurrent High ... Recurrent High ... Recurrent Prima... Recurrent Tripl... Refractory Fall... Refractory Ovar... Refractory Prim... Refractory Trip... Unresectable Hi... Unresectable Ma... Unresectable Pr... | Olaparib Onalespib | 18 Years - | National Cancer Institute (NCI) | |
| Study of ART6043 in Advanced/Metastatic Solid Tumors Patients | NCT05898399 | Advanced Solid ... Metastatic Soli... | ART6043 Olaparib Niraparib Olaparib Niraparib | 18 Years - | Artios Pharma Ltd | |
| A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma | NCT03880019 | Stage III Uteri... Stage IV Uterin... Uterine Corpus ... | Computed Tomogr... Core Biopsy Magnetic Resona... Olaparib Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02446600 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... | Biospecimen Col... Carboplatin Cediranib Malea... Computed Tomogr... Echocardiograph... Gemcitabine Gemcitabine Hyd... Laboratory Biom... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Pharmacological... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | NCT04548752 | Metastatic Panc... Pancreatic Aden... Stage IV Pancre... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Pembrolizumab | 18 Years - | National Cancer Institute (NCI) | |
| Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients | NCT01063517 | Gastric Cancer | olaparib paclitaxel Placebo | 18 Years - 130 Years | AstraZeneca | |
| Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | NCT03878095 | Malignant Solid... Refractory Chol... Refractory Mali... | Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Ceralasertib Computed Tomogr... Magnetic Resona... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors | NCT05700669 | Metastatic Cast... Recurrent Epith... Breast Cancer | AsiDNA Olaparib | 18 Years - | Valerio Therapeutics | |
| Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients | NCT03737643 | Advanced Ovaria... | Bevacizumab Durvalumab Olaparib Placebo olapari... Durvalumab plac... Carboplatin+Pac... | 18 Years - 130 Years | AstraZeneca | |
| Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients | NCT02755844 | Recurrent Endom... | Olaparib metformin metronomic cycl... | 18 Years - 81 Years | Hospices Civils de Lyon | |
| Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer | NCT03150576 | Breast Cancer | Olaparib Paclitaxel and ... | 16 Years - 70 Years | Cambridge University Hospitals NHS Foundation Trust | |
| OSCA - Olaparib Standard of CAre Study | NCT02262273 | Platinum-sensit... | Data Collection | 18 Years - | AstraZeneca | |
| Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC | NCT02686008 | Squamous Cell C... | Olaparib | 18 Years - | Yale University | |
| Olaparib in People With Malignant Mesothelioma | NCT03531840 | Mesothelioma | Olaparib ClinOmics | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant | NCT03259503 | Recurrent Diffu... Recurrent T-Cel... Refractory Diff... Refractory Hodg... Refractory T-Ce... | Busulfan Gemcitabine Melphalan Olaparib Peripheral Bloo... Pharmacokinetic... Rituximab Vorinostat | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer | NCT03532880 | Small-cell Lung... Small Cell Lung... | Olaparib Pill 5... Olaparib Pill 1... Olaparib Pill 1... Olaparib Pill 2... Olaparib Pill 2... Olaparib Pill 3... Radiotherapy | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC | NCT04644289 | Epithelial Ovar... | olaparib durvalumab | 18 Years - | AGO Research GmbH | |
| Olaparib in People With Malignant Mesothelioma | NCT03531840 | Mesothelioma | Olaparib ClinOmics | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer | NCT02822157 | Ovarian Epithel... | Olaparib carboplatin + g... | 18 Years - 100 Years | Universitaire Ziekenhuizen KU Leuven | |
| The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial | NCT03182634 | Advanced Breast... | Fulvestrant Neratinib AZD5363 Olaparib AZD6738 | 18 Years - | Institute of Cancer Research, United Kingdom | |
| A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | NCT03976362 | Carcinoma, Squa... | Pembrolizumab Carboplatin Paclitaxel Nab-paclitaxel Olaparib Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | NCT03924245 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... High Grade Fall... High Grade Ovar... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Primary Periton... Recurrent Endom... Recurrent Ovari... Recurrent Prima... | Entinostat Olaparib | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | NCT03943173 | BRCA-Mutated Ov... BRCA1 Gene Muta... BRCA2 Gene Muta... High Grade Fall... High Grade Ovar... Primary Periton... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... | Chemotherapy Olaparib Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | NCT04753879 | Metastatic Panc... | Nab-paclitaxel Gemcitabine Cisplatin Irinotecan Capecitabine Pembrolizumab Olaparib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients | NCT06121401 | Carcinoma, Ovar... | Olaparib Bevacizumab | 18 Years - 75 Years | Mario Negri Institute for Pharmacological Research | |
| EP0057 in Combination With Olaparib in Advanced Ovarian Cancer | NCT04669002 | Ovarian Cancer | EP0057 Olaparib tablet... | 18 Years - | Ellipses Pharma | |
| Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer | NCT02893917 | Advanced Prosta... Castration-Resi... Metastatic Pros... Metastatic Pros... Prostate Adenoc... Stage IV Prosta... | Cediranib Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy | NCT04666740 | Metastatic Panc... Homologous Reco... | Pembrolizumab Olaparib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer | NCT02855697 | Ovarian Cancer | Olaparib Cediranib Platinum-based ... | 18 Years - | The Christie NHS Foundation Trust | |
| Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients | NCT02681562 | Breast Cancer Triple Negative... | olaparib | 18 Years - 75 Years | Istituti Ospitalieri di Cremona | |
| Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) | NCT02987543 | Metastatic Cast... | olaparib enzalutamide abiraterone ace... abiraterone ace... enzalutamide | 18 Years - 130 Years | AstraZeneca | |
| Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | NCT03740165 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Pembrolizumab Placebo for pem... Carboplatin Paclitaxel Olaparib Placebo for ola... Bevacizumab Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | NCT02419495 | Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re... | Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan | 18 Years - | M.D. Anderson Cancer Center | |
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | NCT04038502 | Metastatic Cast... BARD1, BRCA1, B... RAD51B, RAD51C,... | Carboplatin Olaparib | 18 Years - | VA Office of Research and Development | |
| Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) | NCT04086485 | Gastroenteropan... Neuroendocrine ... Neuroendocrine ... | Lu-177-DOTATATE Olaparib Ga dotatate sca... FDG-PET scannin... Amino Acid infu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations | NCT05498272 | Prostate Cancer BRCA1 Mutation BRCA2 Mutation Prostatic Adeno... High-Risk Cance... | Olaparib LHRH agonist | 18 Years - | Hoosier Cancer Research Network | |
| Pembrolizumab Plus Olaparib in LA-HNSCC | NCT05366166 | Squamous Cell C... | Pembrolizumab Olaparib Cisplatin IMRT (intensity... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | NCT05485766 | Triple Negative... Triple Negative... Breast Neoplasm... Breast Cancer BRCA1 Mutation BRCA2 Mutation BRCA Mutation BRCA-Associated... | Pembrolizumab Paclitaxel Carboplatin Olaparib Definitive Surg... | 18 Years - | Okayama University | |
| Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer | NCT03742245 | Breast Cancer M... Breast Cancer | Olaparib Vorinostat | 18 Years - | The Methodist Hospital Research Institute | |
| Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC | NCT06217757 | Lung Cancer Extensive-stage... | Low-dose radiot... Etoposide Cisplatin Sugemalimab Olaparib | 18 Years - 75 Years | Sichuan University | |
| The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation | NCT05262608 | Prostate Cancer Prostate Carcin... Metastatic Cast... | Olaparib | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer | NCT03740893 | Breast Neoplasm | AZD6738 Olaparib Durvalumab | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status | NCT02983799 | Relapsed Ovaria... | OLAPARIB | 18 Years - 130 Years | AstraZeneca | |
| Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus | NCT01460888 | Carcinoma of th... | Olaparib Radical externa... | 18 Years - | The Christie NHS Foundation Trust | |
| Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor | NCT05536128 | Advanced Breast... | Olaparib Fulvestrant | 19 Years - | Seoul National University Hospital | |
| Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | NCT05286827 | Pancreatic Acin... | Olaparib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Trial of Olaparib in Combination With AZD5363 (ComPAKT) | NCT02338622 | Advanced Cancer | olaparib AZD5363 | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | NCT04643379 | Recurrent Head ... Metastatic Head... | Olaparib Pembrolizumab Carboplatin Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma | NCT01390571 | Brain and Centr... | olaparib temozolomide gene expression... protein express... laboratory biom... pharmacological... diffusion-weigh... dynamic contras... therapeutic con... | 18 Years - | Cancer Research UK | |
| Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | NCT03878095 | Malignant Solid... Refractory Chol... Refractory Mali... | Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Ceralasertib Computed Tomogr... Magnetic Resona... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) | NCT03834519 | Prostatic Neopl... | Pembrolizumab Olaparib Abiraterone ace... Prednisone Enzalutamide Prednisolone | 18 Years - | Merck Sharp & Dohme LLC | |
| Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan | NCT03063710 | PSR Ovarian Can... | olaparib | 18 Years - 130 Years | AstraZeneca | |
| The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. | NCT02430311 | Advanced Solid ... | Olaparib Paclitaxel Olaparib | 18 Years - 130 Years | AstraZeneca | |
| Pembrolizumab and Olaparib in Cervical Cancer Patients | NCT04483544 | Cervical Cancer Cervical Carcin... | pembrolizumab olaparib | 18 Years - | Baptist Health South Florida | |
| Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status | NCT00912743 | Colorectal Canc... | olaparib | 18 Years - 130 Years | AstraZeneca | |
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | NCT02345265 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian High Gr... Ovarian High Gr... Primary Periton... Primary Periton... Primary Periton... | Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | NCT04643379 | Recurrent Head ... Metastatic Head... | Olaparib Pembrolizumab Carboplatin Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | NCT04042831 | Bile Duct Adeno... Fanconi Anemia ... Metastatic Bile... PTEN Gene Delet... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib | 18 Years - | Academic and Community Cancer Research United | |
| Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer | NCT03801369 | Anatomic Stage ... Metastatic Trip... | Biopsy Capivasertib Ceralasertib Durvalumab Olaparib Quality-of-Life... Selumetinib | 18 Years - | OHSU Knight Cancer Institute | |
| A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors | NCT05932862 | Advanced Solid ... | XL309 (ISM3091) Olaparib | 18 Years - | Exelixis | |
| Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers | NCT05379972 | Gastric Cancer GastroEsophagea... | Pembrolizumab Olaparib Stereotactic Bo... | 18 Years - 100 Years | University of Colorado, Denver | |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | NCT02769962 | Urothelial Carc... Urothelial Canc... Lung Neoplasms Small Cell Lung... Prostate Cancer | EP0057 olaparib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Olaparib and Durvalumab in Prostate Cancer | NCT03810105 | Prostate Cancer | Olaparib Durvalumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy | NCT02324998 | Prostate Cancer | Olaparib Degarelix | 18 Years - 73 Years | Cambridge University Hospitals NHS Foundation Trust |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
